Curium’s $8B Lantheus Deal Is a $12-a-Share Warning About Earnouts
An $8 billion deal that pays only $102.50 in cash is not an $8 billion deal. Curium has made Lantheus shareholders carry part of the risk all the way to 2030.
Curium is calling its acquisition of Lantheus an up-to-$8 billion deal. Fair enough. But only $102.50 a share is cash at closing; the remaining $12 a share depends on commercial milestones being hit by 2030.
That is not a minor drafting detail. That is the whole bloody lesson.
Too many founders and investors see the headline number, clap at the premium and stop thinking. The real deal is the money that lands in your account without requiring five years of flawless execution, product uptake, reimbursement progress and zero strategic distractions. Curium has agreed to buy Lantheus for up to $114.50 per share, but $12 of that comes through non-transferable contingent value rights, or CVRs. In plain English: Lantheus shareholders get paid in full only if the business keeps delivering after they no longer own it. ([smb.americustimesrecorder.com](https://smb.americustimesrecorder.com/article/Curium-Announces-Definitive-Agreement-to-Merge-with-Lantheus/6a707c940b3f8c6777521c90?utm_source=openai))
The deal: $102.50 now, $12 later — if the machine keeps humming
On August 3, Curium US Holdings, backed by CapVest, signed a definitive agreement to acquire Lantheus. The transaction gives shareholders $102.50 per share in cash at closing, plus CVRs worth up to another $12 per share. The maximum consideration puts the transaction value at approximately $8 billion. Lantheus’ board approved it unanimously; closing is expected in the first half of 2027, subject to shareholder and regulatory approvals. ([smb.americustimesrecorder.com](https://smb.americustimesrecorder.com/article/Curium-Announces-Definitive-Agreement-to-Merge-with-Lantheus/6a707c940b3f8c6777521c90?utm_source=openai))
The headline premium is substantial. At the maximum $114.50 per share, the offer represented a 38% premium to Lantheus’ unaffected 60-day volume-weighted average price and a 29% premium to its unaffected 30-day VWAP.
But the maximum figure is doing a lot of work there.
The CVRs are tied to specified sales targets. Lantheus shareholders can receive up to $8 a share from global prostate-cancer diagnostics sales targets in fiscal 2030, up to $3 a share from neurology diagnostics sales targets measured across 2028 to 2030, and another $1 a share if the global DEFINITY business reaches its threshold in 2030. The prostate franchise alone needs to clear sales hurdles ranging from more than $950 million to more than $1.75 billion. ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/curium-announces-definitive-agreement-merge-113100522.html?utm_source=openai))
That structure tells you exactly what Curium believes it is buying: not a static collection of approved products, but a commercial engine whose future output is still uncertain enough that the buyer does not want to pay full freight today.
I don’t say that as a criticism. I say it because it is the sort of truth people conveniently misplace when a big number appears in a press release.
Curium is buying the missing half of a platform
This is not a random pharma roll-up. Curium brings a global radiopharmaceutical manufacturing platform and theranostics portfolio. Lantheus brings a major US radiodiagnostics operation, including PYLARIFY in prostate-cancer imaging, the cardiac ultrasound agent DEFINITY, and the amyloid PET imaging agent Neuraceq. The combined company is intended to serve oncology, neurology and cardiology patients in more than 70 countries. ([smb.americustimesrecorder.com](https://smb.americustimesrecorder.com/article/Curium-Announces-Definitive-Agreement-to-Merge-with-Lantheus/6a707c940b3f8c6777521c90?utm_source=openai))
That matters because nuclear medicine is not simply a clever molecule and a sales force. It is a chain of difficult things that have to work together: isotope supply, specialised manufacturing, short shelf lives, regulatory compliance, hospital access, imaging workflows, physician confidence and reimbursement. A promising asset without the machinery to manufacture, distribute and get it used is not a business. It is an expensive science project.
Lantheus has spent years building the commercial side. In 2025, it generated $1.54 billion in revenue. It had also sharpened its focus around innovative PET radiodiagnostics, divesting its legacy SPECT business and signalling that it was examining value-maximising options for radiotherapeutic assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073439/lnth-ex99_1.htm?utm_source=openai))
Curium, meanwhile, had already been valued at about $7 billion in a 2025 recapitalisation by its majority owner, CapVest. Earlier this year, reports said Curium had approached Lantheus about a potential transaction valued around $7 billion. The final agreement is more nuanced: roughly $7 billion of immediate transaction value, with the rest tied to performance. ([news.bloomberglaw.com](https://news.bloomberglaw.com/pharma-and-life-sciences/lantheus-is-said-to-explore-sale-following-offer-from-curium-1?utm_source=openai))
The strategic logic is obvious. Curium gets deeper US commercial reach and recognised diagnostic franchises. Lantheus gets a buyer with broader manufacturing infrastructure and a therapeutic platform. The more interesting point is that both sides are acknowledging that the real prize is not merely diagnosis or therapy. It is owning more of the route between the two.
The overlooked angle: the CVR is a price disagreement with better manners
People often talk about CVRs as if they are clever financial engineering. They are. But they are also a polite way of saying: the buyer and seller did not agree on value.
Curium was prepared to make $102.50 certain. Lantheus and its advisers evidently believed its future commercial portfolio could justify more. Rather than let that disagreement kill the deal, they split the difference and pushed the contested value into milestones.
That can be a sensible solution. It can also be a trap.
For the seller, a CVR is not the same as retaining equity. Lantheus shareholders will not own a stake in the combined company. They will not participate in every upside initiative Curium creates. They have a narrowly defined contractual right to payments if specified targets are achieved.
And those targets will be pursued by a private buyer after the public shareholders are gone.
That does not mean Curium will neglect them. Curium is paying real money for the platform and needs it to grow. But incentives change after closing. Capital allocation changes. Product priorities change. Integration issues turn up. Competitors do competitor things. A CVR holder has none of the control of an owner and none of the certainty of a cash seller.
This is why founders should stop treating earnouts as free upside. They are deferred consideration with operational conditions attached. Sometimes that is the only way to bridge a valuation gap. Fine. Just price them like risk, because they are risk.
Why the deal is bigger than radiopharma
The second-order implication is that specialist healthcare businesses are becoming less valuable as isolated assets and more valuable as pieces of an integrated operating system.
In software, people spent a decade saying distribution eats product. In radiopharma, distribution is more literal: product can have a short usable life, and getting it to the right place at the right time is part of the product itself.
That creates a different type of moat. It is not only patents. It is manufacturing reliability, customer relationships, regulatory know-how and the ability to coordinate a ridiculous number of moving pieces without stuffing it up. Those capabilities compound. They also make M&A more attractive than trying to build every missing component from scratch.
For private equity, this is the appeal and the danger. A platform can justify a premium because the combination may make the whole system more valuable than its parts. But a platform is not a slide deck. It is operations. If Curium and Lantheus cannot integrate manufacturing, commercial teams, pipelines and priorities without slowing down the underlying franchises, the theoretical synergy will be worth exactly what most theoretical synergies are worth: bugger all.
The contrarian read is that the deal is not necessarily a victory for “growth at any price.” The payment structure is almost the opposite. Curium is putting a hard cash floor under the business, then asking former shareholders to prove the aggressive growth case. That is disciplined underwriting dressed up as a large headline.
What this means for you
If you are a founder, operator or investor, nick three lessons from this deal.
First: separate headline value from bankable value. When somebody offers you cash plus an earnout, CVR, rollover equity or performance bonus, create two columns. Column one is guaranteed. Column two is conditional. Make decisions primarily on column one. Hope is not a payment method.
Second: build assets that remove operational bottlenecks. Lantheus was not bought just because it has products. Its commercial infrastructure, diagnostic franchises and US market access matter. Ask yourself: does your company own a capability that takes years to replicate and makes other businesses more useful? That is where strategic value lives.
Third: negotiate the measurement, not just the maximum. If future payments depend on milestones, obsess over the definitions. What counts as revenue? Who controls the budget? What happens if the buyer changes strategy, bundles products, sells an asset or underinvests? A vague earnout is an argument you have agreed to have later, when you have less leverage.
Curium’s Lantheus deal is a serious bet on nuclear medicine. But it is also a tidy reminder for the rest of us: the number in the headline is rarely the number that matters most.
The cash is the deal. Everything else is a forecast wearing a suit.